Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants
Feasibility, Acceptability and Safety of pre-exposure prophylaxis during Pregnancy and Breast Feeding to establish drug thresholds for optimal adherence when FTC/TDF is administered daily under direct observation during pregnancy and in the postpartum period.
• To characterize PrEP adherence among HIV-uninfected adolescent and young adult women (aged 16-24 years) who initiate once-daily emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) in pregnancy and are followed through 6 months postpartum, when offered adherence support through mobile technology and drug level-directed counseling.
• To compare maternal and infant adverse events (including pregnancy outcomes) between women who initiate PrEP and women who decline PrEP over the observation period.
• To identify individual, social, and structural barriers and facilitators to PrEP uptake during pregnancy, and to adherence and continued use during pregnancy and postpartum.
• To compare reported sexual risk behavior and incidence of sexually transmitted infections among women who initiate PrEP during pregnancy and those who decline PrEP over the observation period.
• To compare HIV incidence in women who initiate PrEP during pregnancy and those who decline PrEP over the observation period.
• To compare antiretroviral drug resistance among mothers and infants who acquire HIV with and without exposure to FTC/TDF for PrEP, including whether resistance was transmitted or acquired at time of transmission
IMPAACT 2009 comprises two distinct components: The PK Component is a pharmacokinetic study to establish drug thresholds for optimal adherence when FTC/TDF is administered daily during pregnancy and in the postpartum period. The PrEP Comparison Component is a cohort study that will assess the feasibility, acceptability, and safety of PrEP when provided to adolescents and young women during pregnancy and postpartum.
This study will be conducted among approximately 390 women and their infants (40 in the PK Component, and 350 in the PrEP Comparison Component) who will be selected for the study according to the criteria in Sections 4.1-4.3. The study-specific approach to recruitment, screening, and enrollment is described in Section 4.4. Considerations related to participant retention and withdrawal from the study are provided in Sections 4.5 and 4.6, respectively.
A slightly different population for the two components will be recruited from. In the PrEP Comparison Component, adolescent girls and young women aged 16-24 years are of interest, because this is window of elevated HIV risk for pregnant women. In the PK Component, the lower age limit will be 16 years of age. However, the team has elected not to include an upper age limit. Instead, HIV-uninfected pregnant women 16 years or older can be considered for enrollment, so long as they meet site-specified criteria that account for the social and cultural aspects of daily PrEP adherence. Each site will be asked to develop locally relevant criteria, though this may include factors such as the disclosure of HIV status to family members or the identification of a support partner for daily adherence. Maternal participants will not be stratified in the PK group by age because: a) the overall sample size remains relatively small, limiting its utility for sub-analysis, b) the team looks to enroll rapidly into this initial PK component, and c) the physiological differences between the age groups (i.e., 16-24 years vs. 25 years and older) are unlikely to influence PK parameters over the observation period.
Dr Lee Fairlie, Principal Investigator Dr Masebole Masenya, Sub-Investigator
Latest Update: 23 August 2021
For more about IMPAACT 2009 please email email@example.com